VitaDAO is a community owned collective funding early stage longevity research, governed by $VITA

In this podcast, I (@aging_scientist) spoke with Dr. Rich Miller about the ins and outs of mouse aging.

The topics we discussed, roughly in this order, included the Interventions Testing Program, rapamycin, mecilizine, and other lifespan-extending drugs. We talked about the importance of genetically heterogenous mouse stocks and the issues with fast-aging progeroid mouse models. We also covered his more recent work on aging rate indicators and the difference between classic biomarkers and aging rate indicators. Finally, we talked about the importance of lifespan research, misuse of the word healthspan, and the emerging use of frailty indices in mice.

VitaDAO and Kamil Pabis, MSc (the @Aging_Scientist on Twitter) bring this podcast to you.

Slowing aging by a couple of percents would save more money than curing any single disease, be it cancer, heart disease, or diabetes. Aging is, in fact, the major risk factor that all these diseases have in common. For this reason, slowing aging becomes the most efficient path to a sustainable and healthy future for humanity.

To get this message out we started The Aging Science podcast. We will bring you interviews and frank conversations with leading experts in the field of longevity, as well as evidence-based health advice to support you on this journey.

This podcast is brought to you by VitaDAO and Kamil Pabis, MSc (the @Aging_Scientist on Twitter).

In this podcast, I (@aging_scientist) had the pleasure of interviewing Asst. Prof Alaattin Kaya (@akay_lab).

We talked about recent breakthroughs in the field, the difficulties of getting funding for risky and novel research, funding agencies, “fishing expeditions”, the importance of overexpression genetic screens in aging research, novel mechanisms of action, and the replication crisis.

Insights on Grant-making and Systemic Change: Lessons from Impetus and Beyond with  Martin Borch Jensen & Lada Nuzhna.

Outline: 

0:00 What is Impetus and how did it get started?

Dr Joris Deelen leader at the Max Planck for Biology of AGeing since 2020 and is passionate about research on human aging.

Matt Yousefzadeh, Ph.D., is a postdoctoral fellow in the laboratory of Dr. Laura Niedernhofer, Director of the Institute for the Biology of Aging and Metabolism at the University of Minnesota. He is interested in the mechanisms by which endogenous DNA damage and cellular senescence drive aging.

Dr. Mathieu is a co-founder and the acting Chief Executive Officer of Sentinel Environmental where they are building better microbiomes. Co-founder of Advanced Microbiotics, a startup focused on developing therapeutics to combat antibiotic-resistant bacteria. Did his Ph.D. in environmental engineering at Rice University.

Allison Duettmann is the president of Foresight Institute, a non-profit to advance biotech, nanotech, computing for the long-term benefit of life.

 Dr. Shahaf Peleg is an Independent group leader, Metabolism and epigenetics in aging, FBN (Rostock)

Meet Tim Peterson -  VitaDAO Longevity Steward, Faculty member at Washington University in St. Louis School of Medicine and co-founder of Healthspan Technologies and BIOIO

Tyler Golato is a Biogerontologist, and creative thinker building a more collaborative and open future. He co-founded Molecule and serves as Chief Scientist. He also co-initiated VitaDAO and PsyDAO and is focused on trying to develop new and innovative ways to improve funding processes in drug discovery and development.